Compartmentalization of drug resistance-associated mutations in a treatment-naive HIV-infected female

被引:15
作者
Tirado, G
Jove, G
Kumar, R
Noel, RJ
Reyes, E
Sepulveda, G
Yamamura, Y
Kumar, A
机构
[1] Ponce Sch Med, Dept Microbiol, Lab Viral Immunol, Ponce, PR 00732 USA
[2] Ponce Sch Med, Dept Biochem, Ponce, PR 00732 USA
[3] Dept Hlth Immunol Clin, Arecibo, PR USA
[4] Dept Hlth Immunol Clin, Ponce, PR USA
关键词
D O I
10.1089/0889222041217509
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Development of a drug-resistant variant of HIV-1 has been one of the major concerns contributing to the transmission of the virus. A 40-year-old woman presented to the clinic with micosis and oral candidiasis. The subject was referred for HIV-1 diagnosis. Subsequent investigations revealed a very low CD4 T cell count ( 48 cell/mul blood) and high plasma HIV-1 RNA load (4.33 x 10(5) copy/ml). A 1.3-kb pol fragment was sequenced in virus collected from plasma and the vaginal compartment. Plasma virus had no mutation in reverse transcriptase and one mutation in protease ( L63P). On the other hand vaginal virus contained L63P and M184V mutations in protease and reverse transcriptase, respectively. These mutations were accompanied by several other mutations in previously identified CTL epitopic regions of the two genes. In the absence of antiretroviral treatment, a drug-resistant mutant was thought to develop because of immune pressure. This is the first report describing the role of immune pressure in the development of a drug-resistant virus.
引用
收藏
页码:684 / 686
页数:3
相关论文
共 11 条
[1]  
BETTE K, 2001, HIV MOL IMMUNOLOGY T
[2]  
Brown AJL, 2003, J INFECT DIS, V187, P683, DOI 10.1086/367989
[3]  
D'Aquila Richard T, 2003, Top HIV Med, V11, P92
[4]   Drug concentration heterogeneity facilitates the evolution of drug resistance [J].
Kepler, TB ;
Perelson, AS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (20) :11514-11519
[5]   Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays [J].
Kozal, MJ ;
Shah, N ;
Shen, NP ;
Yang, R ;
Fucini, R ;
Merigan, TC ;
Richman, DD ;
Morris, D ;
Hubbell, ER ;
Chee, M ;
Gingeras, TR .
NATURE MEDICINE, 1996, 2 (07) :753-759
[6]  
Kuritzkes Daniel R, 2002, J HIV Ther, V7, P87
[7]   Antiretroviral-drug resistance among patients recently infected with HIV [J].
Little, SJ ;
Holte, S ;
Routy, JP ;
Daar, ES ;
Markowitz, M ;
Collier, AC ;
Koup, RA ;
Mellors, JW ;
Connick, E ;
Conway, B ;
Kilby, M ;
Wang, L ;
Whitcomb, JM ;
Hellmann, NS ;
Richman, DD .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :385-394
[8]   HIV chemotherapy [J].
Richman, DD .
NATURE, 2001, 410 (6831) :995-1001
[9]   Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals [J].
Simon, V ;
Vanderhoeven, J ;
Hurley, A ;
Ramratnam, B ;
Louie, M ;
Dawson, K ;
Parkin, N ;
Boden, D ;
Markowitz, M .
AIDS, 2002, 16 (11) :1511-1519
[10]   Prevention of mother-to-child transmission of HIV - What next? [J].
Sullivan, JL .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 :S67-S72